The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index; none of the 22 sources its claims cite is checked for support yet.
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
Open accessAbstract
Introduction: Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-effects (NLME) model was developed based on clinical hydrocortisone pharmacokinetic (PK) pediatric and adult data. Additionally, a physiologically-based pharmacokinetic (PBPK) model was developed for adults and a pediatric model was obtained using maturation functions for relevant processes. In this work, a middle-out approach was applied. The aim was to investigate whether PBPK-derived maturation functions could provide a better description of hydrocortisone PK inter-individual variability when implemented in the NLME framework, with the goal of providing better individual predictions towards precision dosing at the patient level. Methods: Hydrocortisone PK data from 24 adrenal insufficiency pediatric patients and 30 adult healthy volunteers were used for NLME model development, while the PBPK model and maturation functions of clearance and cortisol binding globulin (CBG) were developed based on previous studies published in the literature. Results: Clearance (CL) estimates from both approaches were similar for children older than 1 year (CL/F increasing from around 150 L/h to 500 L/h), while CBG concentrations differed across the whole age range (CBG NLME stable around 0.5 μM vs. steady increase from 0.35 to 0.8 μM for CBG PBPK). PBPK-derived maturation functions were subsequently included in the NLME model. After inclusion of the maturation functions, none, a part of, or all parameters were re-estimated. However, the inclusion of CL and/or CBG maturation functions in the NLME model did not result in improved model performance for the CL maturation function (ΔOFV > −15.36) and the re-estimation of parameters using the CBG maturation function most often led to unstable models or individual CL prediction bias. Discussion: Three explanations for the observed discrepancies could be postulated, i) non-considered maturation of processes such as absorption or first-pass effect, ii) lack of patients between 1 and 12 months, iii) lack of correction of PBPK CL maturation functions derived from urinary concentration ratio data for the renal function relative to adults. These should be investigated in the future to determine how NLME and PBPK methods can work towards deriving insights into pediatric hydrocortisone PK.
Overview
CoChat Summary
TL;DR
This paper tested whether PBPK-derived maturation functions for hydrocortisone clearance and CBG binding could improve an NLME pediatric hydrocortisone PK model in children with CAH. The middle-out implementation did not produce a convincing improvement, and the authors conclude that more balanced clinical data—especially in infants 1–12 months old—are needed.
Key findings
- In the NLME vs PBPK comparison, hydrocortisone clearance predictions overlapped reasonably well for children and adults older than 1 year, but showed substantial discrepancies in children younger than 1 year.
- For CBG, the PBPK-derived maturation trend was not represented in the original NLME approach, producing a discrepancy over almost the entire age range.
- Adding the PBPK-derived CL maturation function to the NLME model did not improve fit: using it as fixed worsened the objective function value by ΔOFV = 34.48, and re-estimating PK parameters while keeping it fixed also worsened fit (ΔOFV = 13.25) and led to convergence problems.
- Adding the PBPK-derived CBG maturation function improved fit statistics in some runs (ΔOFV = −26.85, −95.51, −53.1, −133.96 depending on estimation step), but often produced unstable or unrealistic parameter estimates, including a very large condition number (1.19 × 10^8) and high IIV in CL (72.5%).
Methods
- Pediatric data came from an open-label, phase 3, single-center clinical trial in children with adrenal insufficiency, including 23 CAH patients and 1 hypopituitarism patient aged birth to 6 years, with morning oral hydrocortisone granules and plasma cortisol sampling pre-dose, 1 h, and 4 h post-dose, plus extra samples in cohort 1.
- Adult comparison data came from two crossover studies in healthy males aged 18 to 60 years (Infacort-001, n = 16; Infacort-002, n = 14) with multiple plasma sampling time points after immediate-release hydrocortisone granules.
- The analysis compared a previously developed NLME model and a previously developed PBPK model, then implemented PBPK-derived maturation functions for 5α-reductase, 11β-HSD2, and CBG into the NLME framework, evaluating performance by GOF plots, NPDEs, OFV, condition number, parameter precision, and empirical Bayes estimates using FOCE+I in NONMEM.
Limitations
- The paper states that the clinical dataset was sparse, with a notable lack of data between 1 month and 12 months of age, making it difficult to validate the maturation discrepancies in the age range of greatest interest.
- The PBPK-derived maturation functions themselves are uncertain: the 11β-HSD2 and 5α-reductase functions were derived from urinary metabolite ratios that might need correction for renal function, and the CBG function was fitted on variable data with little data beyond 12 months.
- Evident from the text: the study did not assess the impact of these model differences on actual dosing recommendations, saying that this was outside the scope of the work.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 31 Own results and interpretations
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Conversely, relative CL in infants was predicted to be more variable than in children and adults, potentially due to the high activity of 5α-reductase in infants relative to their body size and incomplete maturation processes.”
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As neither the CL nor the CBG maturation function could show convincing improvements in the description of the clinical pediatric dataset, their implementation together in an optimal middle-out model was not successful.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here it can be seen that estimation of the maturation function given the clinical datasets approaches the individual CL estimates as a function of age as fitted by the NLME model without maturation function.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Inclusion of the maturation function without re-estimation of any parameter but including fitting of the individual profiles using empirical Bayes estimates (option MAXEVAL = 0 in NONMEM) resulted in a significantly worse fit as indicated by the OFV (ΔOFV = 34.48).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, large differences in parameter values were observed between the different re-estimation steps, indicating a discrepancy between the modeling approaches or their underlying data.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
16 more claims
Create a free account to see all 42 claims and to verify the 22 references still open.
- It may state two separate claims as one. 17
- The quote only partly states this claim. 1
- Probably not a substantial claim. 7
Citations
Cites
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 1×
“Patients have an increased morbidity and mortality in adult life that may in part relate to suboptimal glucocorticoid therapy in their early years of life (Finkielstain et al., 2012; Han et al., 2014; Bancos et al., 2015; Bornstein et al., 2016).”
BackgroundTissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628 · cited 1×
“Lifelong glucocorticoid replacement therapy with hydrocortisone is standard of care for CAH patients and personalized replacement therapy through precision medicine is essential in optimizing care (Merke and Bornstein, 2005; Hindmarsh, 2009; Kamoun et al., 2013).”
BackgroundJohnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
Self-citationDiagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Brendel, K., Comets, E., Laffont, C., Laveille, C., & Mentré, F. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9067-5 · Cited by 307
Ontogeny of human hepatic cytochromes P450
Hines, R. N. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20179 · Cited by 276
Cited by
Kluwe, F., Michelet, R., Huisinga, W., Zeitlinger, M. A., Mikus, G., & Kloft, C. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01274-y · Cited by 13
Self-citationDeveloping oral chronotherapy for cortisol replacement in congenital adrenal hyperplasia
Whitaker, M. J., Debono, M., & Ross, R. J. M. (2023) · Clinical Endocrinology · doi:10.1111/cen.14976 · Cited by 9
Self-citationBindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09934-7 · Cited by 4
Self-citationBindellini, D., Michelet, R., Mirasbekov, Y., Lao, Q., Sukin, C., Huisinga, W., Merke, D. P., & Kloft, C. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70086 · Cited by 2
Self-citationInnovative Pharmacometric Approaches to Inform Drug Development and Clinical Use
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4503-4
Metadata
- Authors
- Michelet, R., Bindellini, D., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Johnson, T. N., Whitaker, M. J., Ross, R., & Kloft, C.
- Affiliations
- Freie Universität Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University of Potsdam (DE)
- Simcyp (United Kingdom) (GB)
- University of Sheffield (GB)
- Diurnal (United Kingdom) (GB)
- Corresponding author
- Michelet, Robin
- ORCID
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-12
- Volume
- 13
- Pages
- 1090554-1090554
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC9877293
- OpenAlex
- W4315782250
- Semantic Scholar
- c7ee5ae25b75eb36472ff0868c843fcc19eb804a
- Cited by
- 5
- References
- 41
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion, other-oa)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- publish.UP (University of Potsdam) (submittedVersion, cc-by)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- Funders
- Freie Universität Berlin
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- cortisol, congenital adrenal hyperplasia, cortisol replacement therapy, pediatric pharmacokinetics, middle-out approach, physiologically based pharmacokinetic modeling, nonlinear mixed-effects models, interindividual variability, corticosteroid-binding globulin, precision dosing, adrenal insufficiency, renal function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach. https://app.cochat.ai/papers/10.3389/fphar.2022.1090554
- The paper
- Michelet, R., Bindellini, D., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Johnson, T. N., Whitaker, M. J., Ross, R., & Kloft, C. (2023). Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1090554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.